PolyActiva develops PREZIA™, a proprietary covalent‑bond drug‑delivery platform that enables customizable, biodegradable implants and injectable gels for sustained ocular therapy. Its lead asset, PA5108, is a biodegradable ocular implant delivering latanoprost to reduce intraocular pressure in glaucoma and ocular hypertension. Phase 2a results showed clinically relevant IOP reductions for six months from a single implant, and a subset receiving a second implant at 21 weeks had reductions for at least 48 weeks with good tolerability and no negative impact on corneal endothelial cells. The company plans a Phase 2b study to begin in Q3 2025 at clinical sites across the U.S. PolyActiva will accelerate U.S. expansion while maintaining R&D and product development operations in Australia. The recent $25M Series C will support late‑stage clinical advancement of PA5108 and continued development of its broader pipeline enabled by the PREZIA platform. PolyActiva develops proprietary drug-polymer conjugate technology enabling sustained, site-specific drug delivery from rods, films, fibers and gels used in ocular and intra-articular implants. The conjugates carry high drug loads, are designed to erode completely at the end of therapy, and have been proven in validated animal models for delivery to the posterior region of the eye. Its development portfolio includes lower-risk products that deliver established drugs to proven sites and higher-value programs that deliver novel drugs to address unmet clinical needs. Current development programs include intra-ocular implants to treat glaucoma and severe eye infections, and an intra-articular product to treat osteoarthritis. The company plans to advance these programs through preclinical and clinical development and, after demonstrating clinical proof of concept, to seek commercial partners or license its technology to device makers. PolyActiva was founded in 2011 as a joint venture between CSIRO and the Bionic Ear Institute and is located in Melbourne, Australia.

Total raised

$35M

Funding rounds

2

Latest round

Series C

Latest activity

Jun 2025